Search This Blog

Wednesday, May 29, 2019

Northland Capital Markets Starts Opiant Pharma (OPNT) at Outperform

Northland Capital Markets analyst Carl Byrnes initiates coverage on Opiant Pharma (NASDAQ: OPNT) with a Outperform rating and a price target of $42.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.